dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversity Center of Araraquara, UNIARA
dc.date.accessioned2014-05-27T11:27:26Z
dc.date.accessioned2022-10-05T18:40:09Z
dc.date.available2014-05-27T11:27:26Z
dc.date.available2022-10-05T18:40:09Z
dc.date.created2014-05-27T11:27:26Z
dc.date.issued2013-01-01
dc.identifierJournal of Pharmaceutical Sciences, v. 102, n. 1, p. 289-296, 2013.
dc.identifier0022-3549
dc.identifier1520-6017
dc.identifierhttp://hdl.handle.net/11449/74102
dc.identifier10.1002/jps.23368
dc.identifierWOS:000312145900030
dc.identifier2-s2.0-84870714526
dc.identifier9114495952533044
dc.identifier1066743423929093
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3923066
dc.description.abstractDoxorubicin (DOX) is an anthracycline antibiotic with a broad antitumor spectrum. However, the clinical use of DOX is limited because of its cardiotoxicity, a dose-dependent effect. Colloidal drug delivery systems, such as microemulsions (MEs), allow the incorporation of drugs, modifying the pharmacokinetic (PK) profile and toxic effects. In this study, we evaluated the PK profile and cardiotoxicity of a new DOX ME (DOX-ME). The PK profile of DOX-ME was determined and compared with that of the conventional DOX after single-dose administration (6mg/kg, intravenous) in male Wistar rats (n = 12 per group). The cardiotoxicity of DOX formulations was evaluated by serum creatine kinase MB (CKMB) activity in both animal groups before and after drug administration. The plasma DOX measurements were performed by high-performance liquid chromatography with fluorescence detection, and the CKMB levels were assayed using the CKMB Labtest® kit. The ME system showed a significant increase in plasma DOX concentrations and lower distribution volume when compared with conventional DOX. Serum CKMB activity increased after conventional DOX administration but was unchanged in the DOX-ME group. These results demonstrate modifications in drug access to susceptible sites using DOX-ME. DOX-ME displayed features that make it a promising system for future therapeutic application. © 2012 Wiley Periodicals, Inc.
dc.languageeng
dc.relationJournal of Pharmaceutical Sciences
dc.relation3.075
dc.relation0,984
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectBiocompatible microemulsion
dc.subjectCancer chemotherapy
dc.subjectCardiotoxicity
dc.subjectCKMB
dc.subjectDistribution
dc.subjectDoxorubicin
dc.subjectHPLC (High-Performance/Pressure-Liquid-Chromatography)
dc.subjectPharmacokinetics
dc.subjectToxicology
dc.subjectcreatine kinase MB
dc.subjectdoxorubicin
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectbiocompatibility
dc.subjectblood sampling
dc.subjectcardiotoxicity
dc.subjectdrug blood level
dc.subjectdrug formulation
dc.subjectenzyme activity
dc.subjectfluorescence analysis
dc.subjecthigh performance liquid chromatography
dc.subjectmale
dc.subjectmicroemulsion
dc.subjectnonhuman
dc.subjectrat
dc.subjectsingle drug dose
dc.subjectAnimals
dc.subjectAntibiotics, Antineoplastic
dc.subjectBiological Markers
dc.subjectChemistry, Pharmaceutical
dc.subjectChromatography, High Pressure Liquid
dc.subjectCreatine Kinase, MB Form
dc.subjectEmulsions
dc.subjectHeart Diseases
dc.subjectInjections, Intravenous
dc.subjectLipids
dc.subjectMale
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectTechnology, Pharmaceutical
dc.titleBiocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin
dc.typeArtigo


Este ítem pertenece a la siguiente institución